Cyclerion Therapeutics (KRSA) Stock Price, News & Analysis

Company Overview

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.

Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis. The company previously also developed olinciguat and praliciguat for indications including sickle cell disease, diabetic complications and other vascular or metabolic disorders.

Cyclerion was established in 2018 as a spin-off from Ironwood Pharmaceuticals and was headquartered in Cambridge, Massachusetts. It has historically operated as a research and development company rather than a commercial pharmaceutical business, and its programs have been evaluated through clinical development and collaborations rather than through a marketed product portfolio.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KRSA
• CIK: N/A
• Web: www.korsana.com
• Phone: (617) 621-7722
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A